Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949265 | 0.88 | LMNA (0.39) | LMNAL3MBTL1HDAC6HDAC1HDAC2 | |
| SCHEMBL949184 | 0.84 | L3MBTL1 (0.35) | LMNAL3MBTL1HDAC6HDAC1HDAC2 | |
| SCHEMBL12314879 | 0.78 | HDAC6 (0.34) | LMNAHDAC6HDAC1HDAC2CA12 | |
| SCHEMBL15634944 | 0.77 | LMNA (0.39) | LMNAL3MBTL1HDAC6HDAC1HDAC2 | |
| SCHEMBL18195629 | 0.77 | MEN1 (0.36) | L3MBTL1HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL6534709 | 0.77 | HDAC6 (0.33) | L3MBTL1HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL2607007 | 0.76 | MEN1 (0.45) | L3MBTL1HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL948980 | 0.75 | CA12 (0.39) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL22690674 | 0.75 | HDAC6 (0.33) | HDAC6HDAC1HDAC2ALDH1A1HDAC3 | |
| SCHEMBL7488510 | 0.75 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | LMNA 2660/4885L3MBTL1 2949/4885HDAC6 743/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | LMNA 2787/4885L3MBTL1 2955/4885HDAC6 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.